TY - JOUR
T1 - Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour
AU - Okamoto, Yasuyuki
AU - Sawaki, Akira
AU - Ito, Seiji
AU - Nishida, Toshirou
AU - Takahashi, Tsuyoshi
AU - Toyota, Minoru
AU - Suzuki, Hiromu
AU - Shinomura, Yasuhisa
AU - Takeuchi, Ichiro
AU - Shinjo, Keiko
AU - An, Byonggu
AU - Ito, Hidemi
AU - Yamao, Kenji
AU - Fujii, Makiko
AU - Murakami, Hideki
AU - Osada, Hirotaka
AU - Kataoka, Hiromi
AU - Joh, Takashi
AU - Sekido, Yoshitaka
AU - Kondo, Yutaka
PY - 2012/3
Y1 - 2012/3
N2 - Background and aims: The majority of gastrointestinal stromal tumors (GISTs) have KIT mutations; however, epigenetic abnormalities that could conceivably potentiate the aggressiveness of GISTs are largely unidentified. Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs. Methods: Methylation of four tumor suppressor genes, RASSF1A, p16, CDH1, and MGMT was analyzed in GISTs. Additionally, genome-wide DNA methylation profiles were compared between small, malignant-prone, and malignant GISTs using methylated GpG island amplification microarrays (MCAM) in a training set (n=40). Relationships between the methylation status of genes identified by MCAM and clinical features of the disease were tested in a validation set (n=75). Results: Methylation of RASSF1A progressively increased from small to malignant GISTs. p16 was specifically methylated in malignant-prone and malignant GISTs. MCAM analysis showed that more genes were methylated in advanced than in small GISTs (average of 473 genes vs 360 genes, respectively, P=0.012). Interestingly, the methylation profile of malignant GISTs was prominently affected by their location. Two genes, REC8 and PAX3, which were newly-identified via MCAM analysis, were differentially methylated in small and malignant GISTs in the training and validation sets. Patients with methylation of at least REC8, PAX3, or p16 had a significantly poorer prognosis (P=0.034). Conclusion: Our results suggest that GIST is not, in epigenetic terms, a uniform disease and that DNA methylation in a set of genes is associated with aggressive clinical behavior and unfavorable prognosis. The genes identified may potentially serve as biomarkers for predicting aggressive GISTs with poor survivability.
AB - Background and aims: The majority of gastrointestinal stromal tumors (GISTs) have KIT mutations; however, epigenetic abnormalities that could conceivably potentiate the aggressiveness of GISTs are largely unidentified. Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs. Methods: Methylation of four tumor suppressor genes, RASSF1A, p16, CDH1, and MGMT was analyzed in GISTs. Additionally, genome-wide DNA methylation profiles were compared between small, malignant-prone, and malignant GISTs using methylated GpG island amplification microarrays (MCAM) in a training set (n=40). Relationships between the methylation status of genes identified by MCAM and clinical features of the disease were tested in a validation set (n=75). Results: Methylation of RASSF1A progressively increased from small to malignant GISTs. p16 was specifically methylated in malignant-prone and malignant GISTs. MCAM analysis showed that more genes were methylated in advanced than in small GISTs (average of 473 genes vs 360 genes, respectively, P=0.012). Interestingly, the methylation profile of malignant GISTs was prominently affected by their location. Two genes, REC8 and PAX3, which were newly-identified via MCAM analysis, were differentially methylated in small and malignant GISTs in the training and validation sets. Patients with methylation of at least REC8, PAX3, or p16 had a significantly poorer prognosis (P=0.034). Conclusion: Our results suggest that GIST is not, in epigenetic terms, a uniform disease and that DNA methylation in a set of genes is associated with aggressive clinical behavior and unfavorable prognosis. The genes identified may potentially serve as biomarkers for predicting aggressive GISTs with poor survivability.
UR - http://www.scopus.com/inward/record.url?scp=84857046177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857046177&partnerID=8YFLogxK
U2 - 10.1136/gut.2011.241034
DO - 10.1136/gut.2011.241034
M3 - Article
C2 - 21708825
AN - SCOPUS:84857046177
SN - 0017-5749
VL - 61
SP - 392
EP - 401
JO - Gut
JF - Gut
IS - 3
ER -